Idorsia shared positive findings from two new analyses of the pivotal Phase 3 PRECISION study of aprocitentan in patients with resistant hypertension, at the American Heart Association Hypertension… read more.
Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults. Nirogacestat can only be used if… read more.
Biofrontera announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in… read more.
Atara Biotherapeutics, Inc. announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the FDA of the Biologics License Application (BLA) resubmission for tabelecleucel, with… read more.
Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors—commonly leading… read more.
GERPAC Congress 2026 highlights In-process quality control using augmented reality smart glasses (FlexOprep®) reduced risk levels and improved traceability in chemotherapy compounding, according to Loélya Istace (Pharmacy Department,… read more.
Guardant Health announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor… read more.
Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23… read more.
Taking statins is linked to a lower risk of developing glaucoma and a reduced chance of it getting worse, suggest the findings of research published online in the… read more.
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data from the ONWARD Phase 3 clinical… read more.
Novo announced new real-world data from the OCTANE study, an analysis of de-identified data from the Ro telehealth platform. In the study, adults with overweight or obesity who… read more.
Roche announced that the FDA has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
